Healthy Skepticism Library item: 4944

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Regnstrom K, Burgess DJ.
Pharmacogenomics and its potential impact on drug and formulation development.
Crit Rev Ther Drug Carrier Syst 2005; 22:(5):465-92
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4847&uid=16313234&db=PubMed&url=http://www.begellhouse.com/journals/3667c4ae6e8fd136,0f80ebac03395679,22c907bb0f290242.html

Abstract:

Recent advances in genomic research have provided the basis for new insights into the importance of genetic and genomic markers during the different stages of drug development. A new field of research, pharmacogenomics, which studies the relationship between drug effects and the genome, has emerged. Structural pharmacogenomics maps the complete DNA sequences of whole genomes (genotypes) including individual variations, and functional pharmacogenomics assesses the expression levels of thousands of genes in one single experiment. Together, these two areas of pharmacogenomics have generated massive databases, which have become a challenge for the research field of informatics and have fostered a new branch of research, bioinformatics. If skillfully used, the databases generated by pharmacogenomics together with data mining on the Web promise to improve the drug development process in a variety of areas: identification of drug targets, evaluation of toxicity, classification of diseases, evaluation of formulations, assessment of drug response and treatment, post-marketing applications, and development of personalized medicines.

Keywords:
Animals Chemistry, Pharmaceutical/legislation & jurisprudence Chemistry, Pharmaceutical/methods* Computational Biology/legislation & jurisprudence Computational Biology/methods* Drug Evaluation, Preclinical/methods Drug Industry/methods Humans In Vitro Oligonucleotide Array Sequence Analysis Pharmacogenetics/legislation & jurisprudence Pharmacogenetics/methods* Polymorphism, Genetic Product Surveillance, Postmarketing Reverse Transcriptase Polymerase Chain Reaction United States United States Food and Drug Administration